Thiruvananthapuram. Axio Biosolutions, an innovative medical device company based in Boston and Bengaluru, has been actively participating in various military exercises worldwide, including the recent Indo-France Joint Military Exercise (FRINJEX-23) held in Thiruvananthapuram’s Pangode Military Station.

The exercise brought together the Indian Army’s Maratha Light Infantry, French Light Armoured Brigade, and DBLE Brigade for joint military training. During this exercise, Axio Biosolutions showcased its flagship product, Axiostat, a haemostatic dressing that can help stop bleeding in emergency situations. The company is proud to be the sole representative from the medical device industry in the exercise and has a history of actively collaborating with defence forces to provide training on managing combat injuries.

As part of Axio Biosolution’s mission to defend the defenders, its participation in FRINJEX-23 highlighted its collaborations with defence forces to train them on handling combat injuries. The MedTech company also demonstrated the effectiveness of Axiostat and other life-saving products that have been developed specifically for use in high-risk combat zones.

“Our participation in FRINJEX-23 represented a significant opportunity for us to demonstrate our unwavering commitment to defending the defenders,” stated Brijesh, the defence business leader at Axio Biosolutions.

“With our flagship product- Axiostat, we have been credited with saving countless lives on the battlefield and we take great pride in being able to offer this lifesaving solution to defence forces around the world. Although bulletproof (BP) vests and other armour are crucial for soldiers, there are moments when bullets may slip the vest and injure the soldier, which is where Axiostat comes into use. These lightweight, easy-to-carry devices can be stored in BP vests and armoured vehicles, providing effective bleeding control solutions for life-threatening injuries. Our strategic partnerships with defence forces are a crucial aspect of our mission to defend the defenders. We are dedicated to collaborating closely with military personnel to create and deliver products that can save lives even in the most challenging and high-risk environments,” added Brijesh.

In addition to FRINJEX-2023, Axio Biosolutions has played a crucial role in various other military exercises worldwide, including VINBAX – Vietnam, Indo-US, Indo-Oman, and KAZIND – Kazakhstan.

Axio Biosolutions has also conducted demonstrations for various delegations, including Cambodia, Egypt, and the Humanitarian Assistance and Disaster Relief (HADR) exercise- Samanvay, building awareness of innovative ways to stop bleeding in combat situations and save lives.

Axio Biosolutions launched its first-ever military training program, called the Combat Casualty Care (CCC) Program, to reinforce its commitment to “Defending the Defenders.” This program demonstrates and empowers frontline warriors to handle real combat scenarios and save lives.

Incepted in 2008, Axio Biosolutions has developed proprietary products (Axiostat & MaxioCel) using novel biomaterial-based technology for the haemostat and advanced wound care markets globally. The company has built a strong R&D portfolio, with multiple global patents to its credit in the haemostat and wound healing space.

Doctors worldwide utilise the company’s products in interventional cardiology for vascular bleeding control, trauma, and emergency care. These products provide significant value compared to the current standard of care. The company’s flagship Axiostat product range is US FDA 510 (k) cleared and EU CE-approved while MaxioCel is EU CE-approved.